clinical trial · NCT00648024
Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg
HealthyAnagrelide Hydrochloride Capsules 1 mgAgrylin® Capsules 1 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fasting conditions.
started
Jan 1, 2003
primary completion
Jan 1, 2003
completion
Jan 1, 2003
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Anagrelide Hydrochloride Capsules (1 mg; Mylan) to Agrylin® Capsules (1 mg; Shire US) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol